Literature DB >> 18330541

[Use of an outpatient treatment center for cannabis abuse].

F Hölscher1, U Bonnet, N Scherbaum.   

Abstract

BACKGROUND: There has been an increase of cannabis-related disorders in Germany during the last 10 years. According treatments are being established, however little is known about the treatment populations.
METHODS: The population of an outpatient treatment program for diagnosis and therapy of cannabis-related disorders was investigated using a structured interview (based on EuropASI, SCID-I) regarding sociodemographic variables, history of addiction, consumption patterns, and psychiatric comorbidity.
RESULTS: The 90 patients studied had a mean age of 27.5+/-6.6 years; 82% were male. They claimed averages of cannabis consumption for 11+/-7 years and current amount at 1.9 g per day. Alcohol problems were also common in this sample. High percentages were shown regarding unemployment, living alone, and problems with the law. Comorbid psychiatric disorders were diagnosed in 42% of patients.
CONCLUSIONS: The patients were chronic users of cannabis with extensive psychosocial problems. Therapy of cannabis-related disorders should therefore include treatment for comorbidities and social care besides the treatment for addictive behavior.

Entities:  

Mesh:

Year:  2008        PMID: 18330541     DOI: 10.1007/s00115-008-2412-7

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  8 in total

1.  The Marijuana Treatment Project: rationale, design and participant characteristics.

Authors:  Robert S Stephens; Thomas F Babor; Ronald Kadden; Michael Miller
Journal:  Addiction       Date:  2002-12       Impact factor: 6.526

Review 2.  [AWMF-guideline: disorders related to cannabis].

Authors:  U Bonnet; K Harries-Hedder; F M Leweke; U Schneider; P Tossmann
Journal:  Fortschr Neurol Psychiatr       Date:  2004-06       Impact factor: 0.752

3.  Individuals seeking treatment for cannabis-related problems in Ontario: demographic and treatment profile.

Authors:  Karen A Urbanoski; Carol J Strike; Brian R Rush
Journal:  Eur Addict Res       Date:  2005       Impact factor: 3.015

Review 4.  [A survey on trials focussing on the treatment of cannabis-dependence].

Authors:  S Zumdick; U Schneider; M Leweke; A Jülicher; P Tossmann; U Bonnet
Journal:  Fortschr Neurol Psychiatr       Date:  2006-04       Impact factor: 0.752

5.  Problematic drug use and drug use disorders in EU countries and Norway: an overview of the epidemiology.

Authors:  Jürgen Rehm; Robin Room; Wim van den Brink; Ludwig Kraus
Journal:  Eur Neuropsychopharmacol       Date:  2005-08       Impact factor: 4.600

6.  Practice guideline for the treatment of patients with substance use disorders: alcohol, cocaine, opioids. American Psychiatric Association.

Authors: 
Journal:  Am J Psychiatry       Date:  1995-11       Impact factor: 18.112

7.  A comparison of the latent class structure of cannabis problems among adult men and women who have used cannabis repeatedly.

Authors:  Julia D Grant; Jeffrey F Scherrer; Rosalind J Neuman; Alexandre A Todorov; Rumi K Price; Kathleen K Bucholz
Journal:  Addiction       Date:  2006-08       Impact factor: 6.526

Review 8.  [Dual diagnosis of psychosis and addiction. From principles to practice].

Authors:  E Gouzoulis-Mayfrank
Journal:  Nervenarzt       Date:  2004-07       Impact factor: 1.214

  8 in total
  2 in total

1.  Ranking the Harm of Psychoactive Drugs Including Prescription Analgesics to Users and Others-A Perspective of German Addiction Medicine Experts.

Authors:  Udo Bonnet; Michael Specka; Michael Soyka; Thomas Alberti; Stefan Bender; Torsten Grigoleit; Leopold Hermle; Jörg Hilger; Thomas Hillemacher; Thomas Kuhlmann; Jens Kuhn; Christian Luckhaus; Christel Lüdecke; Jens Reimer; Udo Schneider; Welf Schroeder; Markus Stuppe; Gerhard A Wiesbeck; Norbert Wodarz; Heath McAnally; Norbert Scherbaum
Journal:  Front Psychiatry       Date:  2020-10-26       Impact factor: 4.157

2.  Is the Urine Cannabinoid Level Measured via a Commercial Point-of-Care Semiquantitative Immunoassay a Cannabis Withdrawal Syndrome Severity Predictor?

Authors:  Benedikt Bernd Claus; Michael Specka; Heath McAnally; Norbert Scherbaum; Fabrizio Schifano; Udo Bonnet
Journal:  Front Psychiatry       Date:  2020-12-03       Impact factor: 4.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.